首页> 外文期刊>OncoTargets and therapy >MicroRNA-374b-5p Functions as a Tumor Suppressor in Non-Small Cell Lung Cancer by Targeting FOXP1 and Predicts Prognosis of Cancer Patients
【24h】

MicroRNA-374b-5p Functions as a Tumor Suppressor in Non-Small Cell Lung Cancer by Targeting FOXP1 and Predicts Prognosis of Cancer Patients

机译:MicroRNA-374B-5P通过靶向Foxp1并预测癌症患者的预后,用作非小细胞肺癌中的肿瘤抑制剂

获取原文
       

摘要

Background: Lung cancer remains the most frequent malignancy worldwide with increasing morbidity and mortality. This study aimed to assess the expression of microRNA-374b-5p (miR-374b-5p) in tissues and cell lines of non-small cell lung cancer (NSCLC) and to evaluate the prognostic value of miR-374b-5p as well as its biological function in tumor progression. Materials and Methods: Expression of miR-374b-5p in NSCLC patients and cells was estimated using quantitative real-time PCR. The prognostic value of miR-374b-5p was evaluated using Kaplan–Meier method and Cox regression analysis. Gain-of-function and loss-of-function cell experiments were performed to examine the effects of miR-374b-5p on NSCLC cell proliferation, migration and invasion. A luciferase activity assay was used to confirm the target gene of miR-374b-5p. Results: miR-374b-5p expression levels were decreased in tumorous tissues and cell lines compared with the normal tissues or cells ( P 0.05). The expression of miR-374b-5p was associated with the patients’ tumor size, lymph node metastasis and TNM stage (all P 0.05). Patients with low miR-374b-5p expression have a shorter survival time (log-rank P = 0.001), and the downregulated expression of miR-374b-5p was determined to be an independent prognostic indicator of NSCLC. In NSCLC cells, the overexpression of miR-374b-5p could inhibit NSCLC cell proliferation, migration and invasion and could directly target FOXP1. Conclusion: This study found that the decreased miR-374b-5p predicts poor prognosis of NSCLC, and the upregulation of miR-374b-5p can inhibit NSCLC cell proliferation, migration and invasion. The data obtained from this study provide a novel candidate prognostic biomarker and a potential therapeutic target for NSCLC.
机译:背景:肺癌仍然是全世界最常见的恶性肿瘤,发病率增加和死亡率。本研究旨在评估非小细胞肺癌(NSCLC)组织和细胞系中microRNA-374b-5p(miR-374b-5p)的表达,并评估miR-374b-5p的预后值以及其在肿瘤进展中的生物学功能。材料和方法:使用定量实时PCR估计了MiR-374b-5p在NSCLC患者和细胞中的表达。使用Kaplan-Meier方法和Cox回归分析评估miR-374b-5p的预后值。进行功能和功能性细胞实验,以检查miR-374b-5p对Nsclc细胞增殖,迁移和侵袭的影响。荧光素酶活性测定法用于确认miR-374b-5p的靶基因。结果:与正常组织或细胞相比,肿瘤组织和细胞系中MiR-374B-5P表达水平降低(P <0.05)。 miR-374b-5p的表达与患者的肿瘤大小,淋巴结转移和tnm阶段相关(所有p <0.05)。低miR-374b-5p表达的患者具有较短的存活时间(对数级p = 0.001),并且测定miR-374b-5p的下调表达是NSCLC的独立预后指标。在NSCLC细胞中,MIR-374B-5P的过表达可以抑制NSCLC细胞增殖,迁移和侵袭,并且可以直接靶向FOXP1。结论:本研究发现,MIR-374B-5P的下降预测NSCLC预后差,MIR-374B-5P的上调可抑制NSCLC细胞增殖,迁移和侵袭。本研究获得的数据提供了一种新的候选预后生物标志物和NSCLC的潜在治疗靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号